Objectives Acute respiratory distress syndrome and cytokine release syndrome are the major complications of coronavirus disease 2019 (COVID-19) associated with increased …
Background Anakinra might improve the prognosis of patients with moderate to severe COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ …
L Pasin, G Cavalli, P Navalesi, N Sella… - European journal of …, 2021 - Elsevier
Introduction Severe COVID-19 cases have a detrimental hyper-inflammatory host response and different cytokine-blocking biologic agents were explored to improve outcomes …
A Balkhair, I Al-Zakwani, M Al Busaidi… - International Journal of …, 2021 - Elsevier
Objective The aim of this study was to evaluate the efficacy of anakinra in patients who were admitted to hospital for severe COVID-19 pneumonia requiring oxygen therapy. Methods A …
Background Mortality of patients with coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), and systemic inflammation is high. In areas of …
K Dahms, A Mikolajewska, K Ansems… - European journal of …, 2023 - Springer
Background At the end of 2021, the European Medicines Agency (EMA) expanded its approval for the recombinant human interleukin-1 (IL-1) receptor antagonist Anakinra for the …
Objective To report the clinical experience with anakinra in preventing mechanical ventilation in patients with coronavirus disease 2019 (COVID‐19), symptoms of cytokine …
PL Tharaux, G Pialoux, A Pavot, X Mariette… - The Lancet …, 2021 - thelancet.com
Background Patients with COVID-19 pneumonia have an excess of inflammation and increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine …
M Franzetti, A Forastieri, N Borsa… - The Journal of …, 2021 - journals.aai.org
The IL-1 receptor antagonist, anakinra, may represent a therapeutic option for acute respiratory distress syndrome (ARDS) associated with coronavirus disease 2019 (COVID …